This second round of funding raises the equivalent of $45.4 million to support the advancement of Oxford-based Evox’s exosome-based therapeutics pipeline, including pushing several rare disease ...

Evox Therapeutics, a privately held biotechnology ... The company’s internal exosome pipeline is focused on rare, life-threatening diseases with significant unmet need. Its lead product is ...